Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Open Label Extension to Bridging Study CTBM100C2303

Phase 3

Completed

Conditions: Pseudomonas Aeruginosa
Cystic Fibrosis

Interventions: Drug: Tobramycin inhalation powder

First Posted Date: 2009-09-23

Last Posted Date: 2021-06-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 55

Registration Number: NCT00982930

Locations: 🇷🇺
Novartis Investigative Site, Yaroslavl, Russian Federation

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment

Phase 4

Completed

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: Nilotinib

First Posted Date: 2009-09-18

Last Posted Date: 2021-07-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 52

Registration Number: NCT00980018

Locations: 🇺🇸
Presbyterian Hospital of Dallas TexasOncology@PresbyterianHosp, Dallas, Texas, United States
🇺🇸
Texas Oncology Texas Oncology - Sugar Land, Dallas, Texas, United States
🇺🇸
Rocky Mountain Cancer Centers RMCC - Aurora, Greenwood Village, Colorado, United States

and more 17 locations

Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures

Phase 2

Completed

Conditions: Partial Onset Seizures

Interventions: Drug: Placebo to TRI476
Drug: TRI476
Drug: Benzodiazepines

First Posted Date: 2009-09-11

Last Posted Date: 2014-07-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 99

Registration Number: NCT00975715

Locations: 🇯🇵
Novartis Investigative Site, Yamagata, Japan

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Phase 3

Terminated

Conditions: Cancer

Interventions: Biological: Trastuzumab
Drug: Lapatinib

First Posted Date: 2009-08-31

Last Posted Date: 2019-06-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 37

Registration Number: NCT00968968

Locations: 🇨🇦
Novartis Investigative Site, Rimouski, Quebec, Canada

Dose-Escalation Study in Advanced Colon Cancer Patients

Phase 1

Completed

Conditions: Colon Cancer

Interventions: Drug: EPO906 (patupilone)

First Posted Date: 2009-08-31

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT00969046

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: Everolimus

First Posted Date: 2009-08-31

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT00968591

Locations: 🇸🇬
Novartis Investigative Site, Singapore, Singapore

Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects

Phase 1

Terminated

Conditions: Chronic Hepatitis B

Interventions: Drug: albinterferon alfa-2b
Drug: Pegasys®

First Posted Date: 2009-08-25

Last Posted Date: 2011-01-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 141

Registration Number: NCT00964665

Locations: 🇹🇭
Novartis Investigator Site, Songkla, Thailand

Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients

Phase 4

Completed

Conditions: Chronic Renal Failure

Interventions: Drug: Tacrolimus (FK506)
Drug: Everolimus
Drug: Basiliximab
Drug: Enteric Coated Mycophenolate Sodium (EC-MPS)
Drug: Corticosteroids

First Posted Date: 2009-08-25

Last Posted Date: 2014-08-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT00965094

Locations: 🇮🇱
Novartis Investigative Site, Tel-Aviv, Israel

A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients

Phase 2

Completed

Conditions: Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients

Interventions: Drug: Vehicle
Drug: LDE225 0.25%
Drug: LDE225 0.75%

First Posted Date: 2009-08-19

Last Posted Date: 2015-11-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT00961896

Locations: 🇦🇹
Novartis Investigator Site, Vienna, Austria
🇨🇭
Novartis Investigative Site, Zurich, Switzerland

Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: TKI258

First Posted Date: 2009-08-14

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 43

Registration Number: NCT00958971

Locations: 🇺🇸
Texas Oncology, P.A. Presbyterian Hospital, Dallas, Texas, United States
🇺🇸
Comprehensive Blood and Cancer Center Dept CBCC (3), Bakersfield, California, United States
🇺🇸
Tower Cancer Research, Beverly Hills, California, United States

and more 16 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy